Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.55 |
| ▸ | HTR2A | P28223 | 4/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 2/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | HTR1D | P28221 | 1/20 | 0.41 |
| ▸ | HTR1B | P28222 | 1/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9839884 | 0.83 | GABRA1 (0.48) | TAAR1HTR2CHTR2BGABRA1GABRB2 | |
| SCHEMBL681660 | 0.79 | SLC6A4 (0.54) | HTR2AGABRA1GABRB2 | |
| SCHEMBL4843352 | 0.77 | ADRA2A (0.46) | HTR1AHTR2CHTR2BGABRA1GABRB2 | |
| SCHEMBL3842659 | 0.75 | TAAR1 (0.54) | TAAR1HTR2AHTR2CHTR2BHRH1 | |
| SCHEMBL10687325 | 0.75 | TAAR1 (0.59) | TAAR1HTR2AHTR1AHTR2CHTR2B | |
| SCHEMBL6681498 | 0.75 | GABRA1 (0.41) | HTR2CHTR2BGABRA1GABRB2 | |
| SCHEMBL6055136 | 0.75 | GABRA1 (0.48) | HTR2CHTR2BGABRA1GABRB2 | |
| SCHEMBL30606846 | 0.75 | GABRA1 (0.48) | HTR2CHTR2BGABRA1GABRB2 | |
| SCHEMBL20739967 | 0.75 | GABRA1 (0.41) | HTR2CHTR2BGABRA1GABRB2 | |
| Hydrochloric Acid SCHEMBL25189937 | 0.73 | GABRA1 (0.47) | HTR2CHTR2BGABRA1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | MTOR, STAT3, SLC14A1 | TAAR1 4451/4885HTR2A 4862/4885HTR1A 4882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.